Heads Up: (NNVC) Triggers Multiple Bullish Signals On Its Early Move Out Of The Gate

*Sponsored Market Crux Just Announced NanoViricides (NYSE: NNVC) As Its Next Potential Breakout Idea, Starting This Morning—Tuesday, May 20, 2025. Here's What We Can Tell You—So Far… It Just Surpassed All Major Moving Averages Tracked By Barchart. Recently Moved Approximately 63% In Just Under A Month And A Half. Public Float Under 16M Shares Suggests There's The Potential For Significant Swings If Demand Begins To Shift. Market Cap Under $21M Places (NNVC) In A Category Where It Could Witness A Higher Potential For Growth Compared To Larger Companies In The Same Space. May 14 Report Confirms (NNVC) Has Advanced NV-387 Into Phase II For Broader Health Emergency Readiness. Over 1,000 Confirmed Cases Nationwide Highlight Why (NNVC)'s Adaptive Platform Is Drawing Renewed Focus. FDA Has Provided Encouraging Early Feedback On (NNVC)'s NV-HHV-101, Supporting Clinical Pipeline Momentum. Pull Up (NNVC) While It's Still Early… May 20, 2025 This Morning's Coverage: (NNVC) Just Hit Our Radar Dear Reader, Here's a quick update. (NNVC) is currently triggering multiple bullish signals on TradingView's technical analysis tool across the 1, 5, 15, and 30 minute time-frames. In the early session, (NNVC) tapped $1.53, which is above all major moving averages tracked by Barchart. If you missed my earlier coverage, keep reading to get up to speed and see why we're so excited to be bringing you (NNVC) right now. In biotech, the most disruptive advances rarely start with headlines. They start with deep science, focused execution, and the speed to adapt when conditions shift. NanoViricides (NYSE: NNVC) may not be widely known yet, but its recent approximate 63% move—from $0.94 on April 9th to $1.54 by May 16th—put it directly on our radar. With fewer than 16M shares available in the float and a market cap under $23M, NanoViricides (NYSE: NNVC) operates with a lean structure that has the potential to respond swiftly to changing demand. Companies of this size, especially in the biotech sector, can witness significant swings if interest begins to shift. And right now, (NNVC) appears to be flying under the radar—an often-overlooked name in a space dominated by larger players. But with this type of setup, smaller entities often have a clearer runway for growth and strategic execution. Now, with a fresh open at $1.43 today and real-world urgency unfolding in the U.S., NanoViricides (NYSE: NNVC) just moved to the top of our watchlist. This company isn't just adapting to a changing health landscape—it's building for it. Recent Headlines: Focused Response in High-Alert Regions… May 14, 2025 — Quarterly Filing Highlights Phase II Advancements and Broader Emergency Preparedness NanoViricides (NYSE: NNVC) has released its latest fiscal report while confirming progress on NV-387, now entering Phase II evaluation. The company outlined its preparation to respond to multiple emerging health concerns across Africa and other high-priority regions. Read Full Release   May 6, 2025 — Global Alert Levels Rising: NV-387 Being Assessed as a Potential Defense As global health agencies monitor a rise in outbreaks, NanoViricides (NYSE: NNVC)'s NV-387 is gaining attention for its broad-spectrum capabilities. The company is actively developing frontline responses to threats impacting both developing and industrialized regions. Read Full Release March 27, 2025 — Long-Term Threat Forecasts Drive Testing of NV-387 and Related Candidates NanoViricides (NYSE: NNVC) is conducting ongoing evaluations of its nanoviricide® platform against increasingly persistent global health challenges. Attention is turning toward proactive solutions that can adapt to unpredictable shifts in transmission and resistance patterns. Read Full Release → Confirmed Cases Top 1,000 Nationwide as Developers Mobilize… As of mid-May, Texas has reported 718 confirmed cases of a fast-spreading health condition, affecting 32 counties and resulting in multiple fatalities. One county alone—Gaines—accounts for over 400 cases. While new case reports have begun to slow, U.S. totals have now surpassed 1,000 confirmed cases, with public health officials urging caution due to rising summer travel and continued global circulation. In this high-alert climate, NanoViricides (NYSE: NNVC) is advancing NV-387—developed using its proprietary nanoviricide® technology. This innovative approach is designed to mimic human cell receptors, neutralizing harmful agents before they replicate—without relying on immune system activation. As conventional solutions face limits due to evolving resistance patterns, NV-387 presents a highly adaptive alternative that could play a role in broader preparedness efforts. Inside of NanoViricides (NYSE: NNVC)... Behind the scenes, NanoViricides (NYSE: NNVC) owns a mortgage-free, cGMP-certified manufacturing facility in Shelton, CT. It's fully equipped to handle both dr-ug substance and product for clinical supply, allowing the company to reduce costs, avoid delays, and accelerate progress. Beyond NV-387, their pipeline includes NV-HHV-101—targeting shingles and other herpes-related conditions. NV-HHV-101 has shown positive tolerability in studies and is advancing toward human trials. The Science That Stands Apart … NanoViricides (NYSE: NNVC)'s proprietary nanoviricide® platform is more than an innovation—it's a departure from the usual path. Traditional treatments rely on antibodies or other methods that target only parts of a vi-rus, which can be circumvented through mutation. Nanoviricides, on the other hand, replicate the surface of human cells, tricking vi-rus-es into binding as if they were entering a host. Once attached, the nanoviricide engulfs and dismantles the vi-rus—no immune response required. This bind-encapsulate-destroy approach creates a therapeutic pathway that is less vulnerable to vi-rus adaptation. The company's development model is lean and precise. Rather than running costly internal labs, (NNVC) collaborates with academic and government labs for independent testing, ensuring transparent data and efficient capital use. With $10B Market Potential, NanoViricides (NYSE: NNVC) Eyes Major Breakthrough… NanoViricides (NYSE: NNVC) is a leader in developing nanomedicine dr-ugs to target vir-uses using its nanoviricide® technology. This technology mimics host cell receptors to trick vir-uses into binding to the nanoviricide, dismantling them and blocking reinfection, providing a more durable solution than traditional antibodies or vax's. Key points: FDA Progress: Moving toward FDA submission with positive feedback on its NV-HHV-101 dr-ug candidate for herpes vir-uses. Innovative Technology: Nanoviricides can target vir-uses even as they mutate, offering broad protection against Vir-al infections. Manufacturing Facility: The company owns a cGMP-certified facility in Shelton, CT, allowing it to produce dr-ugs in-house, saving time and costs. HerpeCide™ Program: Focused on treating shingles, cold sores, and genital ulcers, with an estimated market size exceeding $10B. Diverse Pipeline: dr-ugs in development for influenza, HIV, Dengue, and Ebola with promising animal model results. Strong IP Portfolio: Exclusive patents for its TheraCour® technology, securing competitive market space. NanoViricides (NYSE: NNVC) is positioned for growth with its breakthrough technology, broad pipeline, and in-house manufacturing, making it a key player in the fight against Vir-al diseases. With momentum building across multiple fronts, (NNVC) is drawing fresh attention from those watching high-alert sectors. Its lean structure, speed of execution, and adaptable science set it apart in a space often dominated by slower-moving giants. And based on everything lining up right now, this may be one of the most timely names to have on radar going into the week. 7 Reasons Why NanoViricides (NYSE: NNVC) Is Topping Our Watchlist This Morning… 1. Recent Market Recognition: An Approximate 63% move in just under a month and a half—from $.94 on April 9 to $1.54 on May 16, 2025, puts (NNVC) directly to the top of our radar. 2. Limited Float: With fewer than 16M shares available in the float and a market cap under $23M, (NNVC) could witness the potential for significant swings if demand begins to shift. 3. Technology Breakthrough: The nanoviricide® platform from (NNVC) is designed to neutralize harmful agents by mimicking human cell receptors—before replication occurs. 4. Phase II Momentum: (NNVC) confirmed that NV-387 is advancing into Phase II evaluation as outlined in its May 14th fiscal report, supporting broader emergency response readiness. 5. Real-World Demand: Rising case counts—now surpassing 1,000 nationwide — underscore the relevance of (NNVC)'s adaptive platform in today's alert-level environment. 6. Manufacturing Control: (NNVC) owns a mortgage-free, cGMP-certified facility in Shelton, CT—positioning the company to move efficiently without third-party bottlenecks. 7. Early Regulatory Traction: Positive early-stage feedback from the FDA for NV-HHV-101 strengthens (NNVC)'s progression toward future clinical milestones. With every major box checked—momentum, innovation, urgency, and infrastructure—(NNVC) is beginning to draw fresh attention. Companies like this don't stay quiet for long—especially when the pace of real-world events begins to catch up with the science. We Have All Eyes On NanoViricides (NYSE: NNVC) This Morning—Tuesday, May 20, 2025… With over 1,000 confirmed cases now reported nationwide—including more than 700 across 32 Texas counties—public health systems remain under pressure, and attention is turning toward proactive developers positioned to respond. NanoViricides (NYSE: NNVC) stands out not only for its recent move but for advancing NV-387 into Phase II, operating from its own in-house cGMP facility, and building a platform designed to intercept fast-evolving threats before replication begins. While others react, NanoViricides (NYSE: NNVC) continues to build ahead of the curve—adapting to a shifting landscape with precision, speed, and an infrastructure ready to execute. This is one low-float name that may no longer fly under the radar for long. We have all eyes on (NNVC) this morning. (NNVC) is currently triggering multiple bullish signals on TradingView's technical analysis tool across the 1, 5, 15, and 30 minute time-frames. Pull up (NNVC) while it's still early. Also—keep an eye out for my next update, it could be on its way to you at any moment. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com ("MarketCrux" or "MC" ) is owned by Headline Media LLC, MC is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 05/19/2025 and ending on 05/20/2025 to publicly disseminate information about (NNVC:US) via digital communications. Under this agreement, Headline Media LLC has been paid seven thousand five hundred USD ("Funds"). To date, including under the previously described agreement, Headline Media LLC has been paid fifteen thousand USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Headline Media LLC, TD Media LLC and their member own shares of (NNVC:US). Please see important disclosure information here: https://marketcrux.com/disclosure/nnvc-LEnXM/#details

Headline Media | 7901 4th Street N, Suite 300, St. Petersburg, FL 33702 Unsubscribe {recipient's email} Update Profile | Constant Contact Data Notice Sent by gary@marketcrux.net powered by Try email marketing for free today!